Konstas Anastasios G P, Katsanos Andreas, Quaranta Luciano, Mikropoulos Dimitrios G, Tranos Paris G, Teus Miguel A
1st University Department of Ophthalmology, Aristotle University, Thessaloniki, Greece; 3rd University Department of Ophthalmology, Aristotle University, Thessaloniki, Greece; Ophthalmica Institute, Thessaloniki, Greece.
Ophthalmology Department, University of Ioannina, Ioannina, Greece.
Prog Brain Res. 2015;221:297-318. doi: 10.1016/bs.pbr.2015.06.010. Epub 2015 Sep 9.
Current medical therapy of glaucoma aims to attain a meaningful and consistent reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which will commensurate with either stability, or delayed progression of visual loss. Glaucoma is a 24-h disease and the damaging effect of elevated IOP is continuous. Therefore, it is reasonable that we should endeavor to identify the true efficacy of currently available and future antiglaucoma medications throughout the 24-h period. This review chapter deals first with the concept and value of diurnal and 24-h pressure monitoring. It then evaluates existing evidence on the 24-h efficacy of medical therapy options. Unfortunately, significant gaps exist in our present understanding of the short-term and particularly the long-term 24-h efficacy of most antiglaucoma medications. More long-term controlled evidence is needed in the future to improve our understanding of the 24-h efficacy of current medical glaucoma therapy, the ideal 24-h target pressure and the precise impact of IOP characteristics upon the different stages of the various forms of glaucoma.
当前青光眼的药物治疗旨在将眼内压(IOP)有意义且持续地降低至预定的目标眼压水平,这将与视力丧失的稳定或延缓进展相适应。青光眼是一种24小时发病的疾病,眼压升高的损害作用是持续的。因此,我们应努力确定现有及未来抗青光眼药物在24小时内的真实疗效,这是合理的。本章综述首先探讨昼夜眼压监测和24小时眼压监测的概念及价值。然后评估药物治疗方案24小时疗效的现有证据。遗憾的是,目前我们对大多数抗青光眼药物的短期,尤其是长期24小时疗效的认识存在重大差距。未来需要更多长期对照证据,以增进我们对当前青光眼药物治疗24小时疗效、理想的24小时目标眼压以及眼压特征对各种类型青光眼不同阶段的确切影响的理解。